{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:49:12Z","timestamp":1790887752862,"version":"4.1.0"},"reference-count":195,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:00:00Z","timestamp":1645056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004329","name":"Slovenian Research Agency","doi-asserted-by":"publisher","award":["L3-9279"],"award-info":[{"award-number":["L3-9279"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Von Hippel-Lindau disease (VHL disease or VHL syndrome) is a familial multisystem neoplastic syndrome stemming from germline disease-associated variants of the VHL tumor suppressor gene on chromosome 3. VHL is involved, through the EPO-VHL-HIF signaling axis, in oxygen sensing and adaptive response to hypoxia, as well as in numerous HIF-independent pathways. The diverse roles of VHL confirm its implication in several crucial cellular processes. VHL variations have been associated with the development of VHL disease and erythrocytosis. The association between genotypes and phenotypes still remains ambiguous for the majority of mutations. It appears that there is a distinction between erythrocytosis-causing VHL variations and VHL variations causing VHL disease with tumor development. Understanding the pathogenic effects of VHL variants might better predict the prognosis and optimize management of the patient.<\/jats:p>","DOI":"10.3390\/genes13020362","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T20:25:45Z","timestamp":1645129545000},"page":"362","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["The Role of VHL in the Development of von Hippel-Lindau Disease and Erythrocytosis"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2546-0674","authenticated-orcid":false,"given":"Petra","family":"Hudler","sequence":"first","affiliation":[{"name":"Medical Centre for Molecular Biology, Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8007-834X","authenticated-orcid":false,"given":"Mojca","family":"Urbancic","sequence":"additional","affiliation":[{"name":"Eye Hospital, University Medical Centre Ljubljana, Grabloviceva ulica 46, 1000 Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000345668","article-title":"von Hippel-Lindau syndrome","volume":"41","author":"Chou","year":"2013","journal-title":"Front. Horm. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/B978-0-444-62702-5.00010-X","article-title":"Von Hippel-Lindau disease","volume":"132","author":"Chittiboina","year":"2015","journal-title":"Handb. Clin. Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(03)13643-4","article-title":"von Hippel-Lindau disease","volume":"361","author":"Lonser","year":"2003","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"384","DOI":"10.3171\/2014.2.JNS131190","article-title":"De novo VHL germline mutation detected in a patient with mild clinical phenotype of von Hippel-Lindau disease","volume":"121","author":"Ding","year":"2014","journal-title":"J. Neurosurg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/ana.20704","article-title":"Second hit deletion size in von Hippel-Lindau disease","volume":"59","author":"Glasker","year":"2006","journal-title":"Ann. Neurol."},{"key":"ref_6","first-page":"542","article-title":"Outcome and genetic analysis of patients affected by retinal capillary hemangioblastoma in von Hippel Lindau syndrome","volume":"27","author":"Murro","year":"2021","journal-title":"Mol. Vis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1093\/hmg\/4.11.2139","article-title":"Molecular analysis of de novo germline mutations in the von Hippel-Lindau disease gene","volume":"4","author":"Richards","year":"1995","journal-title":"Hum. Mol. Genet."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/ng1019","article-title":"Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia","volume":"32","author":"Ang","year":"2002","journal-title":"Nat. Genet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/humu.20385","article-title":"Genotype-phenotype correlations in von Hippel-Lindau disease","volume":"28","author":"Ong","year":"2007","journal-title":"Hum. Mutat."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/hmg\/6.7.1051","article-title":"Genetic predisposition to phaeochromocytoma: Analysis of candidate genes GDNF, RET and VHL","volume":"6","author":"Woodward","year":"1997","journal-title":"Hum. Mol. Genet."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/humu.22448","article-title":"Genetic basis of congenital erythrocytosis: Mutation update and online databases","volume":"35","author":"Bento","year":"2014","journal-title":"Hum. Mutat."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1097\/IAE.0000000000002555","article-title":"VON HIPPEL-LINDAU DISEASE: Update on Pathogenesis and Systemic Aspects","volume":"39","author":"Aronow","year":"2019","journal-title":"Retina"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1126\/science.8493574","article-title":"Identification of the von Hippel-Lindau disease tumor suppressor gene","volume":"260","author":"Latif","year":"1993","journal-title":"Science"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/sj.onc.1202473","article-title":"Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity","volume":"18","author":"Blankenship","year":"1999","journal-title":"Oncogene"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/blood-2018-03-838235","article-title":"Identification of a new VHL exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease","volume":"132","author":"Lenglet","year":"2018","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"11661","DOI":"10.1073\/pnas.95.20.11661","article-title":"pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation","volume":"95","author":"Iliopoulos","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/hmg\/5.5.639","article-title":"Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis","volume":"5","author":"Richards","year":"1996","journal-title":"Hum. Mol. Genet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"8817","DOI":"10.1073\/pnas.95.15.8817","article-title":"A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor","volume":"95","author":"Schoenfeld","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"D733","DOI":"10.1093\/nar\/gkv1189","article-title":"Reference sequence (RefSeq) database at NCBI: Current status, taxonomic expansion, and functional annotation","volume":"44","author":"Wright","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"D480","DOI":"10.1093\/nar\/gkaa1100","article-title":"UniProt: The universal protein knowledgebase in 2021","volume":"49","author":"UniProt","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1126\/science.1073440","article-title":"Structure of an HIF-1alpha -pVHL complex: Hydroxyproline recognition in signaling","volume":"296","author":"Min","year":"2002","journal-title":"Science"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1126\/science.284.5413.455","article-title":"Structure of the VHL-ElonginC-ElonginB complex: Implications for VHL tumor suppressor function","volume":"284","author":"Stebbins","year":"1999","journal-title":"Science"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1016\/j.febslet.2009.10.070","article-title":"Adding structural information to the von Hippel-Lindau (VHL) tumor suppressor interaction network","volume":"583","author":"Leonardi","year":"2009","journal-title":"FEBS Lett."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1006\/bbrc.1999.1347","article-title":"Direct interaction of the \u03b2-domain of VHL tumor suppressor protein with the regulatory domain of atypical PKC isotypes","volume":"263","author":"Okuda","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cpbi.5","article-title":"The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses","volume":"54","author":"Stelzer","year":"2016","journal-title":"Curr. Protoc. Bioinform."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1074\/mcp.M113.035600","article-title":"Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics","volume":"13","author":"Fagerberg","year":"2014","journal-title":"Mol. Cell Proteom."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e8503","DOI":"10.15252\/msb.20188503","article-title":"A deep proteome and transcriptome abundance atlas of 29 healthy human tissues","volume":"15","author":"Wang","year":"2019","journal-title":"Mol. Syst. Biol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Perl, K., Ushakov, K., Pozniak, Y., Yizhar-Barnea, O., Bhonker, Y., Shivatzki, S., Geiger, T., Avraham, K.B., and Shamir, R. (2017). Reduced changes in protein compared to mRNA levels across non-proliferating tissues. BMC Genom., 18.","DOI":"10.1186\/s12864-017-3683-9"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1038\/onc.2011.442","article-title":"Complex cellular functions of the von Hippel-Lindau tumor suppressor gene: Insights from model organisms","volume":"31","author":"Hsu","year":"2012","journal-title":"Oncogene"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s13046-020-01733-5","article-title":"Epigenetic crosstalk between hypoxia and tumor driven by HIF regulation","volume":"39","author":"Li","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/j.ajpath.2020.04.003","article-title":"Understanding the Oxygen-Sensing Pathway and Its Therapeutic Implications in Diseases","volume":"190","author":"Liao","year":"2020","journal-title":"Am. J. Pathol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Tomc, J., and Debeljak, N. (2021). Molecular Insights into the Oxygen-Sensing Pathway and Erythropoietin Expression Regulation in Erythropoiesis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22137074"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrc885","article-title":"Molecular basis of the VHL hereditary cancer syndrome","volume":"2","author":"Kaelin","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nm0895-822","article-title":"Tumour suppression by the human von Hippel-Lindau gene product","volume":"1","author":"Iliopoulos","year":"1995","journal-title":"Nat. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.7660130","article-title":"Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C","volume":"269","author":"Kibel","year":"1995","journal-title":"Science"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1074\/jbc.270.3.1230","article-title":"Purification and characterization of hypoxia-inducible factor 1","volume":"270","author":"Wang","year":"1995","journal-title":"J. Biol. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"10595","DOI":"10.1073\/pnas.93.20.10595","article-title":"Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein","volume":"93","author":"Iliopoulos","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1128\/MCB.18.2.732","article-title":"Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B\/C and Cul2","volume":"18","author":"Lonergan","year":"1998","journal-title":"Mol. Cell Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/20459","article-title":"The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis","volume":"399","author":"Maxwell","year":"1999","journal-title":"Nature"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1126\/science.1059817","article-title":"HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing","volume":"292","author":"Ivan","year":"2001","journal-title":"Science"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1126\/science.1059796","article-title":"Targeting of HIF-\u03b1 to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation","volume":"292","author":"Jaakkola","year":"2001","journal-title":"Science"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10409238.2013.838205","article-title":"Transcriptional regulation by hypoxia inducible factors","volume":"49","author":"Dengler","year":"2014","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1515\/BC.2004.016","article-title":"HIF hydroxylation and cellular oxygen sensing","volume":"385","author":"Metzen","year":"2004","journal-title":"Biol. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"30772","DOI":"10.1074\/jbc.M304982200","article-title":"Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor","volume":"278","author":"Hirsila","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"6415","DOI":"10.1128\/MCB.25.15.6415-6426.2005","article-title":"Coordinate regulation of the oxygen-dependent degradation domains of hypoxia-inducible factor 1 \u03b1","volume":"25","author":"Chan","year":"2005","journal-title":"Mol. Cell Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"13041","DOI":"10.1074\/jbc.M110.211110","article-title":"Differential sensitivity of hypoxia inducible factor hydroxylation sites to hypoxia and hydroxylase inhibitors","volume":"286","author":"Tian","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"167244","DOI":"10.1016\/j.jmb.2021.167244","article-title":"HIF-1alpha Hydroxyprolines Modulate Oxygen-Dependent Protein Stability Via Single VHL Interface With Comparable Effect on Ubiquitination Rate","volume":"433","author":"He","year":"2021","journal-title":"J. Mol. Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"26351","DOI":"10.1074\/jbc.C200273200","article-title":"Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family","volume":"277","author":"Hewitson","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1126\/science.1068592","article-title":"Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch","volume":"295","author":"Lando","year":"2002","journal-title":"Science"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"39887","DOI":"10.1074\/jbc.M205040200","article-title":"The von Hippel-Lindau tumor suppressor stabilizes novel plant homeodomain protein Jade-1","volume":"277","author":"Zhou","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"5371","DOI":"10.1158\/0008-5472.CAN-12-4707","article-title":"Candidate tumor suppressor and pVHL partner Jade-1 binds and inhibits AKT in renal cell carcinoma","volume":"73","author":"Zeng","year":"2013","journal-title":"Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1083\/jcb.200605092","article-title":"The von Hippel-Lindau tumor suppressor protein controls ciliogenesis by orienting microtubule growth","volume":"175","author":"Schermer","year":"2006","journal-title":"J. Cell Biol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.ejca.2013.02.024","article-title":"Genetic deletion of the long isoform of the von Hippel-Lindau tumour suppressor gene product alters microtubule dynamics","volume":"49","author":"Frew","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/ncb1912","article-title":"VHL loss causes spindle misorientation and chromosome instability","volume":"11","author":"Thoma","year":"2009","journal-title":"Nat. Cell Biol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"12069","DOI":"10.1074\/jbc.M511621200","article-title":"Endocytic function of von Hippel-Lindau tumor suppressor protein regulates surface localization of fibroblast growth factor receptor 1 and cell motility","volume":"281","author":"Hsu","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"17023","DOI":"10.1038\/cddiscovery.2017.23","article-title":"RalBP1 and p19-VHL play an oncogenic role, and p30-VHL plays a tumor suppressor role during the blebbishield emergency program","volume":"3","author":"Jinesh","year":"2017","journal-title":"Cell Death Discov."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.molcel.2007.09.010","article-title":"pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2","volume":"28","author":"Yang","year":"2007","journal-title":"Mol. Cell."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1073\/pnas.0436037100","article-title":"von Hippel-Lindau protein binds hyperphosphorylated large subunit of RNA polymerase II through a proline hydroxylation motif and targets it for ubiquitination","volume":"100","author":"Kuznetsova","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1128\/MCB.01231-07","article-title":"The von Hippel-Lindau tumor suppressor protein and Egl-9-Type proline hydroxylases regulate the large subunit of RNA polymerase II in response to oxidative stress","volume":"28","author":"Mikhaylova","year":"2008","journal-title":"Mol. Cell Biol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1093\/emboj\/cdg410","article-title":"Identification of the RNA polymerase II subunit hsRPB7 as a novel target of the von Hippel-Lindau protein","volume":"22","author":"Na","year":"2003","journal-title":"EMBO J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1158\/0008-5472.CAN-05-3236","article-title":"von Hippel-Lindau tumor suppressor protein regulates the assembly of intercellular junctions in renal cancer cells through hypoxia-inducible factor-independent mechanisms","volume":"66","author":"Calzada","year":"2006","journal-title":"Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1097-2765(00)80096-9","article-title":"The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix","volume":"1","author":"Ohh","year":"1998","journal-title":"Mol. Cell"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/s41598-020-58137-w","article-title":"pVHL-mediated regulation of the anti-angiogenic protein thrombospondin-1 decreases migration of Clear Cell Renal Carcinoma Cell Lines","volume":"10","author":"Ordonez","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1128\/MCB.26.7.2519-2530.2006","article-title":"pVHL function is essential for endothelial extracellular matrix deposition","volume":"26","author":"Tang","year":"2006","journal-title":"Mol. Cell Biol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/carcin\/bgn275","article-title":"von Hippel-Lindau tumor suppressor gene-dependent mRNA stabilization of the survival factor parathyroid hormone-related protein in human renal cell carcinoma by the RNA-binding protein HuR","volume":"30","author":"Danilin","year":"2009","journal-title":"Carcinogenesis"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"7083","DOI":"10.1128\/MCB.23.20.7083-7095.2003","article-title":"Influence of the RNA-binding protein HuR in pVHL-regulated p53 expression in renal carcinoma cells","volume":"23","author":"Galban","year":"2003","journal-title":"Mol. Cell Biol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1158\/1541-7786.MCR-11-0435","article-title":"Association of the von Hippel-Lindau protein with AUF1 and posttranscriptional regulation of VEGFA mRNA","volume":"10","author":"Xin","year":"2012","journal-title":"Mol. Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ccr.2008.03.012","article-title":"VHL inactivation: A new road to senescence","volume":"13","author":"Kim","year":"2008","journal-title":"Cancer Cell"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/ncb1699","article-title":"VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400","volume":"10","author":"Young","year":"2008","journal-title":"Nat. Cell Biol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/onc.2013.22","article-title":"K63-ubiquitylation of VHL by SOCS1 mediates DNA double-strand break repair","volume":"33","author":"Metcalf","year":"2014","journal-title":"Oncogene"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nm.2370","article-title":"Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia","volume":"17","author":"Russell","year":"2011","journal-title":"Nat. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1021\/pr200642c","article-title":"Proteomic dissection of the von Hippel-Lindau (VHL) interactome","volume":"10","author":"Lai","year":"2011","journal-title":"J. Proteome Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"12605","DOI":"10.1038\/srep12605","article-title":"Isoform-specific interactions of the von Hippel-Lindau tumor suppressor protein","volume":"5","author":"Minervini","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1038\/ncb1802","article-title":"Arginine methylation regulates the p53 response","volume":"10","author":"Jansson","year":"2008","journal-title":"Nat. Cell Biol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.molcel.2006.04.006","article-title":"p53 stabilization and transactivation by a von Hippel-Lindau protein","volume":"22","author":"Roe","year":"2006","journal-title":"Mol. Cell"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.bbrc.2017.05.180","article-title":"Centrosomal MCM7 strengthens the Cep68-VHL interaction and excessive MCM7 leads to centrosome splitting resulting from increase in Cep68 ubiquitination and proteasomal degradation","volume":"489","author":"Kong","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1038\/onc.2016.495","article-title":"Ubiquitination and regulation of AURKA identifies a hypoxia-independent E3 ligase activity of VHL","volume":"36","author":"Hasanov","year":"2017","journal-title":"Oncogene"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"D607","DOI":"10.1093\/nar\/gky1131","article-title":"STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets","volume":"47","author":"Szklarczyk","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40618-017-0683-1","article-title":"Von Hippel-Lindau disease: A single gene, several hereditary tumors","volume":"41","author":"Crespigio","year":"2018","journal-title":"J. Endocrinol. Investig."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/jjco\/hyl052","article-title":"Von Hippel-Lindau disease: Molecular pathological basis, clinical criteria, genetic testing, clinical features of tumors and treatment","volume":"36","author":"Shuin","year":"2006","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.3389\/fonc.2019.01037","article-title":"Hemangioblastoma Instead of Renal Cell Carcinoma Plays a Major Role in the Unfavorable Overall Survival of Von Hippel-Lindau Disease Patients","volume":"9","author":"Zhou","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/humu.1380050109","article-title":"Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: Correlations with phenotype","volume":"5","author":"Chen","year":"1995","journal-title":"Hum. Mutat."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"27","DOI":"10.15586\/jkcvhl.v9i1.206","article-title":"Von Hippel-Lindau Syndrome: Medical Syndrome or Surgical Syndrome? A Surgical Perspective","volume":"9","author":"Coco","year":"2022","journal-title":"J. Kidney Cancer VHL"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"858","DOI":"10.3803\/EnM.2020.683","article-title":"Genetic Analysis and Clinical Characteristics of Hereditary Pheochromocytoma and Paraganglioma Syndrome in Korean Population","volume":"35","author":"Choi","year":"2020","journal-title":"Endocrinol. Metab."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"31128","DOI":"10.1038\/srep31128","article-title":"VHLdb: A database of von Hippel-Lindau protein interactors and mutations","volume":"6","author":"Tabaro","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"D941","DOI":"10.1093\/nar\/gky1015","article-title":"COSMIC: The Catalogue Of Somatic Mutations In Cancer","volume":"47","author":"Tate","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s40142-019-00180-9","article-title":"von Hippel-Lindau Disease: An Update","volume":"7","author":"Maher","year":"2019","journal-title":"Curr. Genet. Med. Rep."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Hacker, K.E., Lee, C.M., and Rathmell, W.K. (2008). VHL type 2B mutations retain VBC complex form and function. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0003801"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Buart, S., Terry, S., Diop, M.K., Dessen, P., Couve, S., Abdou, A., Adam, J., Thiery, J., Savagner, P., and Chouaib, S. (2021). The Most Common VHL Point Mutation R167Q in Hereditary VHL Disease Interferes with Cell Plasticity Regulation. Cancers, 13.","DOI":"10.3390\/cancers13153897"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/hmg\/10.10.1019","article-title":"von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF","volume":"10","author":"Hoffman","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ccr.2005.06.015","article-title":"Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: Developmental culling and cancer","volume":"8","author":"Lee","year":"2005","journal-title":"Cancer Cell"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41419-021-04135-3","article-title":"Deubiquitylase OTUD6B stabilizes the mutated pVHL and suppresses cell migration in clear cell renal cell carcinoma","volume":"13","author":"Guo","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"867","DOI":"10.3389\/fgene.2019.00867","article-title":"Frequent Mutations of VHL Gene and the Clinical Phenotypes in the Largest Chinese Cohort With Von Hippel-Lindau Disease","volume":"10","author":"Hong","year":"2019","journal-title":"Front. Genet."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"7985","DOI":"10.1074\/jbc.M413160200","article-title":"Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL.hypoxia-inducible transcription factor-1alpha complex","volume":"280","author":"Miller","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/prot.22419","article-title":"Structural bioinformatics mutation analysis reveals genotype-phenotype correlations in von Hippel-Lindau disease and suggests molecular mechanisms of tumorigenesis","volume":"77","author":"Forman","year":"2009","journal-title":"Proteins"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/jhg.2014.61","article-title":"Germline mutation of Glu70Lys is highly frequent in Korean patients with von Hippel-Lindau (VHL) disease","volume":"59","author":"Hwang","year":"2014","journal-title":"J. Hum. Genet."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/ncb899","article-title":"Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL","volume":"5","author":"Hergovich","year":"2003","journal-title":"Nat. Cell Biol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3892\/etm.2020.8829","article-title":"Clinical diagnosis, treatment and screening of the VHL gene in three von Hippel-Lindau disease pedigrees","volume":"20","author":"Lin","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1074\/jbc.M108269200","article-title":"Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein","volume":"277","author":"Li","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"25733","DOI":"10.1074\/jbc.M002740200","article-title":"Hypoxia inducible factor-\u03b1 binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein","volume":"275","author":"Cockman","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"44323","DOI":"10.1074\/jbc.M104678200","article-title":"Selection of mutant CHO cells with constitutive activation of the HIF system and inactivation of the von Hippel-Lindau tumor suppressor","volume":"276","author":"Vaux","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/sj.onc.1209062","article-title":"Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1alpha interactions","volume":"25","author":"Knauth","year":"2006","journal-title":"Oncogene"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1038\/sj.onc.1209328","article-title":"Homotypic association between tumour-associated VHL proteins leads to the restoration of HIF pathway","volume":"25","author":"Chung","year":"2006","journal-title":"Oncogene"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1128\/MCB.00282-07","article-title":"Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations","volume":"27","author":"Li","year":"2007","journal-title":"Mol. Cell Biol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S1097-2765(03)00423-4","article-title":"Tumorigenic mutations in VHL disrupt folding in vivo by interfering with chaperonin binding","volume":"12","author":"Feldman","year":"2003","journal-title":"Mol. Cell"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1128\/MCB.22.6.1947-1960.2002","article-title":"Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity","volume":"22","author":"Hansen","year":"2002","journal-title":"Mol. Cell Biol."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Shmueli, M.D., Schnaider, L., Rosenblum, D., Herzog, G., Gazit, E., and Segal, D. (2013). Structural insights into the folding defects of oncogenic pVHL lead to correction of its function in vitro. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0066333"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/s41388-018-0491-x","article-title":"Arginine refolds, stabilizes, and restores function of mutant pVHL proteins in animal model of the VHL cancer syndrome","volume":"38","author":"Shmueli","year":"2019","journal-title":"Oncogene"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1172\/JCI8161","article-title":"Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein","volume":"104","author":"Ohh","year":"1999","journal-title":"J. Clin. Investig."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1083\/jcb.201006059","article-title":"Quantitative image analysis identifies pVHL as a key regulator of microtubule dynamic instability","volume":"190","author":"Thoma","year":"2010","journal-title":"J. Cell Biol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"6554","DOI":"10.1158\/0008-5472.CAN-14-1161","article-title":"Genetic evidence of a precisely tuned dysregulation in the hypoxia signaling pathway during oncogenesis","volume":"74","author":"Couve","year":"2014","journal-title":"Cancer Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.febslet.2007.02.059","article-title":"PKCzetaII is a target for degradation through the tumour suppressor protein pVHL","volume":"581","author":"Iturrioz","year":"2007","journal-title":"FEBS Lett."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.4161\/cc.22794","article-title":"Estrogen receptor \u03b1 is a novel target of the Von Hippel-Lindau protein and is responsible for the proliferation of VHL-deficient cells under hypoxic conditions","volume":"11","author":"Jung","year":"2012","journal-title":"Cell Cycle"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e92193","DOI":"10.1172\/jci.insight.92193","article-title":"Von Hippel-Lindau mutations disrupt vascular patterning and maturation via Notch","volume":"3","author":"Arreola","year":"2018","journal-title":"JCI Insight"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"8595","DOI":"10.1158\/0008-5472.CAN-04-1430","article-title":"In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations","volume":"64","author":"Rathmell","year":"2004","journal-title":"Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1158\/0008-5472.CAN-05-2560","article-title":"Characterization of a von Hippel Lindau pathway involved in extracellular matrix remodeling, cell invasion, and angiogenesis","volume":"66","author":"Kurban","year":"2006","journal-title":"Cancer Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41419-019-1507-3","article-title":"von Hippel-Lindau mutants in renal cell carcinoma are regulated by increased expression of RSUME","volume":"10","author":"Tedesco","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"de Rojas, P.I., Albinana, V., Taranets, L., Recio-Poveda, L., Cuesta, A.M., Popov, N., Kronenberger, T., and Botella, L.M. (2021). The Endothelial Landscape and Its Role in Von Hippel-Lindau Disease. Cells, 10.","DOI":"10.3390\/cells10092313"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"5669","DOI":"10.2147\/OTT.S190753","article-title":"Von Hippel-Lindau Disease: Current Challenges and Future Prospects","volume":"13","author":"Glasker","year":"2020","journal-title":"Onco Targets Ther."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nature12222","article-title":"Comprehensive molecular characterization of clear cell renal cell carcinoma","volume":"499","author":"Creighton","year":"2013","journal-title":"Nature"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1182\/blood.V92.9.3388","article-title":"Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function","volume":"92","author":"Krieg","year":"1998","journal-title":"Blood"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11912-019-0752-z","article-title":"HIF Inhibitors: Status of Current Clinical Development","volume":"21","author":"Fallah","year":"2019","journal-title":"Curr. Oncol. Rep."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1055\/s-2006-939441","article-title":"Vascular complications in Chuvash polycythemia","volume":"32","author":"Gordeuk","year":"2006","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.bbrc.2005.08.165","article-title":"The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing","volume":"338","author":"Kaelin","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/nature10275","article-title":"A continuum model for tumour suppression","volume":"476","author":"Berger","year":"2011","journal-title":"Nature"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1006\/bcmd.2002.0488","article-title":"Endemic polycythemia in Russia: Mutation in the VHL gene","volume":"28","author":"Ang","year":"2002","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_128","first-page":"30","article-title":"Familial erythrocytosis among inhabitants of the Chuvash ASSR","volume":"10","author":"Polyakova","year":"1974","journal-title":"Probl. Gematol. Pereliv. Krovi"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1182\/blood.V89.6.2148","article-title":"Congenital polycythemia in Chuvashia","volume":"89","author":"Sergeyeva","year":"1997","journal-title":"Blood"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/ejhg.2010.175","article-title":"von Hippel-Lindau disease: A clinical and scientific review","volume":"19","author":"Maher","year":"2011","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1007\/s00381-020-04712-5","article-title":"Hemangioblastoma and von Hippel-Lindau disease: Genetic background, spectrum of disease, and neurosurgical treatment","volume":"36","author":"Klingler","year":"2020","journal-title":"Childs Nerv. Syst."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1227\/01.NEU.0000159646.15026.D6","article-title":"Hemangioblastomas of central nervous system: Molecular genetic analysis and clinical management","volume":"56","author":"Catapano","year":"2005","journal-title":"Neurosurgery"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/jmedgenet-2019-106336","article-title":"Novel genetic characterisation and phenotype correlation in von Hippel-Lindau (VHL) disease based on the Elongin C binding site: A large retrospective study","volume":"57","author":"Xie","year":"2020","journal-title":"J. Med. Genet."},{"key":"ref_134","first-page":"78","article-title":"Von Hippel-Lindau Disease and the Eye","volume":"15","author":"Karimi","year":"2020","journal-title":"J. Ophthalmic Vis. Res."},{"key":"ref_135","first-page":"e5319","article-title":"Ocular Manifestations of von Hippel-Lindau Disease","volume":"11","author":"Ruppert","year":"2019","journal-title":"Cureus"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0039-6257(01)00245-4","article-title":"von Hippel-Lindau disease","volume":"46","author":"Singh","year":"2001","journal-title":"Surv. Ophthalmol."},{"key":"ref_137","first-page":"495","article-title":"Ocular manifestations of von Hippel-Lindau disease: Clinical and genetic investigations","volume":"103","author":"Chew","year":"2005","journal-title":"Trans. Am. Ophthalmol. Soc."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/aos.14360","article-title":"Retinal haemangioblastomas in von Hippel-Lindau germline mutation carriers: Progression, complications and treatment outcome","volume":"98","author":"Hajjaj","year":"2020","journal-title":"Acta Ophthalmol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archopht.125.2.239","article-title":"Genotype-phenotype correlation in von Hippel-Lindau disease with retinal angiomatosis","volume":"125","author":"Wong","year":"2007","journal-title":"Arch. Ophthalmol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ophtha.2007.03.009","article-title":"Clinical characterization of retinal capillary hemangioblastomas in a large population of patients with von Hippel-Lindau disease","volume":"115","author":"Wong","year":"2008","journal-title":"Ophthalmology"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1016\/j.ophtha.2012.06.026","article-title":"Longitudinal analysis of retinal hemangioblastomatosis and visual function in ocular von Hippel-Lindau disease","volume":"119","author":"Toy","year":"2012","journal-title":"Ophthalmology"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1001\/archopht.1995.01100090089027","article-title":"Retinal vascular hamartoma in von Hippel-Lindau disease","volume":"113","author":"Schmidt","year":"1995","journal-title":"Arch. Ophthalmol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0002-9394(88)90181-X","article-title":"Twin vessels in von Hippel-Lindau disease","volume":"105","author":"Verkaart","year":"1988","journal-title":"Am. J. Ophthalmol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/archopht.126.5.637","article-title":"Retinal vascular proliferation as an ocular manifestation of von Hippel-Lindau disease","volume":"126","author":"Wong","year":"2008","journal-title":"Arch. Ophthalmol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/13816810.2014.886265","article-title":"Genotype-phenotype correlations, and retinal function and structure in von Hippel-Lindau disease","volume":"35","author":"Wittstrom","year":"2014","journal-title":"Ophthalm. Genet."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Lu, Y., Wang, J.C., Zeng, R., Nagata, T., Katz, R., Mukai, S., and Miller, J.B. (2020). Detection of retinal microvascular changes in von Hippel-Lindau disease using optical coherence tomography angiography. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0229213"},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Pilotto, E., Nacci, E.B., Ferrara, A.M., De Moja, G., Zovato, S., and Midena, E. (2020). Macular Perfusion Impairment in Von Hippel-Lindau Disease Suggests a Generalized Retinal Vessel Alteration. J. Clin. Med., 9.","DOI":"10.3390\/jcm9082677"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41598-020-79652-w","article-title":"Structural and microvascular changes of the peripapillary retinal nerve fiber layer in Von Hippel-Lindau disease: An OCT and OCT angiography study","volume":"11","author":"Pilotto","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3389\/fonc.2020.00139","article-title":"von Hippel-Lindau Syndrome: Genetic Study of Case With a Rare Pathogenic Variant With Optic Nerve Hemangioblastoma, a Rare Phenotypic Expression","volume":"10","author":"Boratto","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"683021","DOI":"10.3389\/fonc.2021.683021","article-title":"Central Nervous System Hemangioblastoma in a Pediatric Patient Associated With Von Hippel-Lindau Disease: A Case Report and Literature Review","volume":"11","author":"Yang","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13256-015-0539-2","article-title":"Pathology characteristics of ocular von Hippel-Lindau disease with neovascularization of the iris and cornea: A case report","volume":"9","author":"Chen","year":"2015","journal-title":"J. Med. Case Rep."},{"key":"ref_152","first-page":"3067","article-title":"Retinal hemangioblastoma in von Hippel-Lindau disease: A clinical and molecular study","volume":"43","author":"Dollfus","year":"2002","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.1167\/iovs.10-5223","article-title":"Genotype-phenotype correlation in ocular von Hippel-Lindau (VHL) disease: The effect of missense mutation position on ocular VHL phenotype","volume":"51","author":"Mettu","year":"2010","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"237","DOI":"10.18632\/oncotarget.27428","article-title":"Prevalence and clinical significance of VHL mutations and 3p25 deletions in renal tumor subtypes","volume":"11","author":"Buscheck","year":"2020","journal-title":"Oncotarget"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"eaal5272","DOI":"10.1126\/scitranslmed.aal5272","article-title":"HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase","volume":"9","author":"Chakraborty","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41581-020-00359-2","article-title":"Clear cell renal cell carcinoma ontogeny and mechanisms of lethality","volume":"17","author":"Jonasch","year":"2021","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1073\/pnas.1619726114","article-title":"Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL-\/- clear cell renal carcinoma","volume":"114","author":"Gao","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Testa, U., Pelosi, E., and Castelli, G. (2020). Genetic Alterations in Renal Cancers: Identification of The Mechanisms Underlying Cancer Initiation and Progression and of Therapeutic Targets. Medicines, 7.","DOI":"10.3390\/medicines7080044"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/ng.2891","article-title":"Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing","volume":"46","author":"Gerlinger","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/ng.2699","article-title":"Integrated molecular analysis of clear-cell renal cell carcinoma","volume":"45","author":"Sato","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1210\/jc.2010-1946","article-title":"Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: Primary tumor size and primary tumor location as prognostic indicators","volume":"96","author":"Feng","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"586857","DOI":"10.3389\/fendo.2020.586857","article-title":"The VHL\/HIF Axis in the Development and Treatment of Pheochromocytoma\/Paraganglioma","volume":"11","author":"Peng","year":"2020","journal-title":"Front. Endocrinol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1007\/s12094-021-02622-9","article-title":"Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas","volume":"23","author":"Robledo","year":"2021","journal-title":"Clin. Transl. Oncol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1530\/EC-20-0208","article-title":"Clinical decision making in small non-functioning VHL-related incidentalomas","volume":"9","author":"Darr","year":"2020","journal-title":"Endocr. Connect."},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Guha, A., Vicha, A., Zelinka, T., Musil, Z., and Chovanec, M. (2021). Genetic Variants in Patients with Multiple Head and Neck Paragangliomas: Dilemma in Management. Biomedicines, 9.","DOI":"10.3390\/biomedicines9060626"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1055\/s-0031-1301302","article-title":"An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes","volume":"44","author":"Dahia","year":"2012","journal-title":"Horm. Metab. Res."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1210\/me.2010-0256","article-title":"Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas","volume":"24","author":"Munoz","year":"2010","journal-title":"Mol. Endocrinol."},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Tsoli, M., Daskalakis, K., Kassi, E., Kaltsas, G., and Tsolakis, A.V. (2021). A Critical Appraisal of Contemporary and Novel Biomarkers in Pheochromocytomas and Adrenocortical Tumors. Biology, 10.","DOI":"10.3390\/biology10070580"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"598656","DOI":"10.3389\/fendo.2021.598656","article-title":"Seven Novel Genes Related to Cell Proliferation and Migration of VHL-Mutated Pheochromocytoma","volume":"12","author":"Gao","year":"2021","journal-title":"Front. Endocrinol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41419-021-03731-7","article-title":"GIPC2 is an endocrine-specific tumor suppressor gene for both sporadic and hereditary tumors of RET- and SDHB-, but not VHL-associated clusters of pheochromocytoma\/paraganglioma","volume":"12","author":"Dong","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"671","DOI":"10.4149\/neo_2018_181208N933","article-title":"A systematic review on the genetic analysis of paragangliomas: Primarily focused on head and neck paragangliomas","volume":"66","author":"Guha","year":"2019","journal-title":"Neoplasma"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"R293","DOI":"10.1530\/EC-21-0294","article-title":"Pheochromocytomas and paragangliomas in von Hippel-Lindau disease: Not a needle in a haystack","volume":"10","author":"Rebelo","year":"2021","journal-title":"Endocr. Connect."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1210\/jc.2019-00235","article-title":"A synonymous VHL variant in exon 2 confers susceptibility to familial pheochromocytoma and von Hippel-Lindau disease","volume":"104","author":"Flores","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1136\/jmedgenet-2019-106519","article-title":"Germline mutations in the new E1\u2032 cryptic exon of the VHL gene in patients with tumours of von Hippel-Lindau disease spectrum or with paraganglioma","volume":"57","author":"Buffet","year":"2020","journal-title":"J. Med. Genet."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/neuonc\/nox034","article-title":"Differences in genetic and epigenetic alterations between von Hippel-Lindau disease-related and sporadic hemangioblastomas of the central nervous system","volume":"19","author":"Takayanagi","year":"2017","journal-title":"Neuro. Oncol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/(SICI)1098-1004(1998)12:6<424::AID-HUMU9>3.0.CO;2-H","article-title":"Germline mutation profile of the VHL gene in von Hippel-Lindau disease and in sporadic hemangioblastoma","volume":"12","author":"Olschwang","year":"1998","journal-title":"Hum. Mutat."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/(SICI)1098-1004(1998)12:6<417::AID-HUMU8>3.0.CO;2-K","article-title":"Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene","volume":"12","author":"Stolle","year":"1998","journal-title":"Hum. Mutat."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1751-553X.2008.01102.x","article-title":"The classification and diagnosis of erythrocytosis","volume":"30","author":"McMullin","year":"2008","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"6353","DOI":"10.1182\/bloodadvances.2020003323","article-title":"Erythrocytosis in the general population: Clinical characteristics and association with clonal hematopoiesis","volume":"4","author":"Wouters","year":"2020","journal-title":"Blood Adv."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41408-021-00463-x","article-title":"Phenotypical differences and thrombosis rates in secondary erythrocytosis versus polycythemia vera","volume":"11","author":"Nguyen","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1001\/jama.1971.03180150077023","article-title":"Eye manifestations in polycythemia","volume":"215","author":"Ascher","year":"1971","journal-title":"JAMA"},{"key":"ref_182","first-page":"Doc38","article-title":"Management of macular edema with branch retinal vein occlusion in a case of secondary polycythemia","volume":"9","author":"Singh","year":"2019","journal-title":"GMS Ophthalmol. Cases"},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Liisborg, C., Hasselbalch, H.C., and Sorensen, T.L. (2020). Ocular Manifestations in Patients with Philadelphia-Negative Myeloproliferative Neoplasms. Cancers, 12.","DOI":"10.3390\/cancers12030573"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/bjh.12290","article-title":"Delayed choroidal and retinal blood flow in polycythaemia vera patients with transient ocular blindness: A preliminary study with fluorescein angiography","volume":"161","author":"Yang","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"McMullin, M.F. (2021). Genetic Background of Congenital Erythrocytosis. Genes, 12.","DOI":"10.3390\/genes12081151"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1086\/377108","article-title":"Mutations of von Hippel-Lindau tumor-suppressor gene and congenital polycythemia","volume":"73","author":"Pastore","year":"2003","journal-title":"Am. J. Hum. Genet."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"D789","DOI":"10.1093\/nar\/gku1205","article-title":"OMIM.org: Online Mendelian Inheritance in Man (OMIM(R)), an online catalog of human genes and genetic disorders","volume":"43","author":"Amberger","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1182\/blood-2002-10-3246","article-title":"Chuvash-type congenital polycythemia in 4 families of Asian and Western European ancestry","volume":"102","author":"Percy","year":"2003","journal-title":"Blood"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1182\/blood-2003-07-2535","article-title":"Congenital disorder of oxygen sensing: Association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors","volume":"103","author":"Gordeuk","year":"2004","journal-title":"Blood"},{"key":"ref_190","first-page":"298","article-title":"The VHL Tumor Suppressor Gene: Insights into Oxygen Sensing and Cancer","volume":"128","author":"Kaelin","year":"2017","journal-title":"Trans. Am. Clin. Climatol. Assoc."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3324\/haematol.2012.070508","article-title":"The phenotype of polycythemia due to Croatian homozygous VHL (571C>G:H191D) mutation is different from that of Chuvash polycythemia (VHL 598C>T:R200W)","volume":"98","author":"Tomasic","year":"2013","journal-title":"Haematologica"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood-2013-10-534222","article-title":"RUNX1 and NF-E2 upregulation is not specific for MPNs, but is seen in polycythemic disorders with augmented HIF signaling","volume":"123","author":"Kapralova","year":"2014","journal-title":"Blood"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1002\/pbc.25056","article-title":"The homozygous VHL(D126N) missense mutation is associated with dramatically elevated erythropoietin levels, consequent polycythemia, and early onset severe pulmonary hypertension","volume":"61","author":"Sarangi","year":"2014","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1182\/blood-2012-11-469296","article-title":"Novel homozygous VHL mutation in exon 2 is associated with congenital polycythemia but not with cancer","volume":"121","author":"Lanikova","year":"2013","journal-title":"Blood"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1609987","DOI":"10.3389\/pore.2021.1609987","article-title":"rs779805 Von Hippel-Lindau Gene Polymorphism Induced\/Related Polycythemia Entity, Clinical Features, Cancer Association, and Familiar Characteristics","volume":"27","author":"Remenyi","year":"2021","journal-title":"Pathol. Oncol. Res."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/13\/2\/362\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:21:28Z","timestamp":1760134888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/13\/2\/362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,17]]},"references-count":195,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["genes13020362"],"URL":"https:\/\/doi.org\/10.3390\/genes13020362","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,17]]}}}